» Articles » PMID: 34440663

Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, Before and After Parathyroidectomy

Overview
Journal Cells
Publisher MDPI
Date 2021 Aug 27
PMID 34440663
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Primary hyperparathyroidism (PHPT) is the most common endocrinopathy in multiple endocrine neoplasia type 1 (MEN1). Persistent levels of increased parathyroid hormone (PTH) result in a higher incidence of osteopenia and osteoporosis compared to the general population. Surgical removal of hyper-functioning parathyroid tissue is the therapy of choice. This retrospective study evaluated the effect of parathyroidectomy (PTX) on bone metabolism and bone mass in two series of patients with MEN1 PHPT and sporadic PHPT (sPHPT) by comparing bone metabolism-related biochemical markers and bone mineral density (BMD) before and after surgery. Our data confirmed, in a higher number of cases than in previously published studies, the efficacy of PTX, not only to rapidly restore normal levels of PTH and calcium, but also to normalize biochemical parameters of bone resorption and bone formation, and to improve spine and femur bone mass, in both MEN1 PHPT and sPHPT. Evaluation of single-patient BMD changes after surgery indicates an individual variable bone mass improvement in a great majority of MEN1 PHPT patients. In MEN1 patients, PTX is strongly suggested in the presence of increased PTH and hypercalcemia to prevent/reduce the early-onset bone mass loss and grant, in young patients, the achievement of the bone mass peak; routine monitoring of bone metabolism and bone mass should start from adolescence. Therapy with anti-fracture drugs is indicated in MEN1 patients with BMD lower than the age-matched normal values.

Citing Articles

Minerals and Human Health: From Deficiency to Toxicity.

Razzaque M, Wimalawansa S Nutrients. 2025; 17(3).

PMID: 39940312 PMC: 11820417. DOI: 10.3390/nu17030454.


Genotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.

Kubo H, Wada R, Sekikawa N, Nomura Y, Yamada M, Inoue M Front Endocrinol (Lausanne). 2024; 15:1498991.

PMID: 39726845 PMC: 11669518. DOI: 10.3389/fendo.2024.1498991.


Bone mineral density over ten years after primary parathyroidectomy in multiple endocrine neoplasia type 1.

Kuusela E, Kostiainen I, Ritvonen E, Ryhanen E, Schalin-Jantti C JBMR Plus. 2024; 8(12):ziae129.

PMID: 39575107 PMC: 11579653. DOI: 10.1093/jbmrpl/ziae129.


Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies.

Iwanowska M, Kochman M, Szatko A, Zgliczynski W, Glinicki P Int J Mol Sci. 2024; 25(21).

PMID: 39519190 PMC: 11546563. DOI: 10.3390/ijms252111639.


Analysis of Bone Phenotype Differences in MEN1-Related and Sporadic Primary Hyperparathyroidism Using 3D-DXA.

Eremkina A, Pylina S, Elfimova A, Gorbacheva A, Humbert L, Picazo M J Clin Med. 2024; 13(21).

PMID: 39518523 PMC: 11546830. DOI: 10.3390/jcm13216382.


References
1.
Lourenco Jr D, Coutinho F, Toledo R, Montenegro F, Correia-Deur J, Toledo S . Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J Bone Miner Res. 2010; 25(11):2382-91. DOI: 10.1002/jbmr.125. View

2.
Thakker R, Newey P, Walls G, Bilezikian J, Dralle H, Ebeling P . Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9):2990-3011. DOI: 10.1210/jc.2012-1230. View

3.
Lourenco Jr D, Coutinho F, Toledo R, Goncalves T, Montenegro F, Toledo S . Biochemical, bone and renal patterns in hyperparathyroidism associated with multiple endocrine neoplasia type 1. Clinics (Sao Paulo). 2012; 67 Suppl 1:99-108. PMC: 3329618. DOI: 10.6061/clinics/2012(sup01)17. View

4.
Giusti F, Cianferotti L, Gronchi G, Cioppi F, Masi L, Faggiano A . Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine. 2015; 52(3):495-506. DOI: 10.1007/s12020-015-0696-5. View

5.
Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, Levy-Bohbot N . MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015; 100(4):1568-77. DOI: 10.1210/jc.2014-3659. View